PH-responsive hydrogels with dispersed hydrophobic nanoparticles for the oral delivery of chemotherapeutics

Journal of Biomedical Materials Research - Part A

Volumn 101 A, Issue 8, 2013, Pages 2229-2236

  Schoener, Cody A ^a   Hutson, Heather N ^a   Peppas, Nicholas A ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

controlled release; doxorubicin; hydrogels; nanoparticles; oral delivery; pH responsive

Indexed keywords

AMPHIPHILIC POLYMERS; CONTROLLED RELEASE; DOXORUBICIN; HYDROPHOBIC NANOPARTICLES; ORAL DELIVERY; PH-RESPONSIVE; PH-RESPONSIVE HYDROGELS; PHYSIO-CHEMICAL PROPERTIES;

CELL CULTURE; DISEASES; ETHYLENE GLYCOL; HYDROGELS; HYDROPHOBICITY; PHYSIOLOGICAL MODELS; POLYMER FILMS; POLYMERS;

NANOPARTICLES;

DOXORUBICIN; ETHYLENE GLYCOL; NANOPARTICLE; POLYMETHACRYLIC ACID;

ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG RELEASE; DRUG SYNTHESIS; HYDROGEL; HYDROPHOBICITY; MUCOADHESION; NONHUMAN; PH; SMALL INTESTINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; HUMANS; HYDROGELS; HYDROGEN-ION CONCENTRATION; INTESTINE, SMALL; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS; SWINE;

EID: 84879504285     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34532     Document Type: Article

References (62)

1. Blanchette J, Kavimandan N, Peppas NA,. Principles of transmucosal delivery of therapeutic agents. Biomed Pharmacother 2004; 58: 142-151.
2. Liu G, Franssen E, Fitch MI, Warner E,. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
3. Irshad S, Maisey N,. Considerations when choosing oral chemotherapy: Identifying and responding to patient need. Eur J Cancer Care 2010; 19: 5-11.
4. Mao JH, Balmain A,. Genomic approaches to identification of tumour-susceptibility genes using mouse models. Curr Opin Genet Dev 2003; 13: 14-19.
5. Ohmori K, Sasaki K, Asada S, Tanaka N, Umeda M,. An assay method for the prediction of tumor promoting potential of chemicals by the use of Bhas 42 cells. Mutat Res-Gen Tox En 2004; 557: 191-202.
6. Schrenk D, Schmitz HJ, Bohnenberger S, Wagner B, Worner W,. Tumor promoters as inhibitors of apoptosis in rat hepatocytes. Toxicol Lett 2004; 149: 43-50.
7. Wolfle D,. Enhancement of carcinogen-induced malignant cell transformation by prostaglandin F-2 alpha. Toxicology 2003; 188: 139-147.
8. Van Cutsem E, Twelves C, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
9. Boeck S, Wilkowski R, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology-Basel 2007; 73: 221-227.
10. Beach DF, Somer R,. Novel approach to gorlin syndrome: A patient treated with oral capecitabine. J Clin Oncol 2011; 29: E397-E401.
11. Bowater R, Abdelmalik S, Lilford R,. Efficacy of adjuvant chemotherapy after surgery when considered over all cancer types: A synthesis of meta-analyses. Ann Surgl Oncol 2012;doi: 10.1245/s10434-012-2388-1.
12. Hamidi M, Azadi A, Rafiei P,. Hydrogel nanoparticles in drug delivery. Adv Drug Delivery Rev 2008; 60: 1638-1649.
13. Caldorera-Moore M, Guimard N, Shi L, Roy K,. Designer nanoparticles: incorporating size, shape and triggered release in nanoscale drug carriers. Expert Opin Drug Deliv 2010; 7: 479-495.
14. Schoener CA, Hutson HN, Fletcher GK, Peppas NA,. Amphiphilic interpenetrating networks for the delivery of hydrophobic, low molecular weight therapeutic agents. Ind Eng Chem Res 2011; 50: 12556-12561.
15. Zhang J, Peppas NA,. Synthesis and characterization of pH- and temperature-sensitive poly(methacrylic acid)/poly(N-isopropylacrylamide) interpenetrating polymeric networks. Macromolecules 2000; 33: 102-107.
16. Peppas NA, Bures P, Leobandung W, Ichikawa H,. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000; 50: 27-46.
17. Peppas NA, Huang Y, Torres-Lugo M, Ward JH, Zhang J,. Physicochemical fooundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng 2000; 2: 9-29.
18. Peppas NA, Wood KM, Blanchette JO,. Hydrogels for oral delivery of therapeutic proteins. Expert Opin Biol Ther 2004; 4: 881-887.
19. Gil ES, Hudson SM,. Stimuli-reponsive polymers and their bioconjugates. Prog Polym Sci 2004; 29: 1173-1222.
20. Marek SR, Conn CA, Peppas NA,. Cationic nanogels based on diethylaminoethyl methacrylate. Polymer 2010; 51: 1237-1243.
21. Phillips MA, Gran ML, Peppas NA,. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010; 5: 143-159.
22. Pool-Zobel BL, Van Loo J, Rowland I, Roberfroid M,. Experimental evidences on the potential of prebiotic fructans to reduce the risk of colon cancer. Br J Nutr 2002; 87: S273-S281.
23. Peppas NA, Kavimandan NJ,. Nanoscale analysis of protein and peptide absorption: Insulin absorption using complexation and pH-senstive hydrogels as delivery vehicles. EurJ Pharm Sci 2006; 29: 183-197.
24. Peppas NA, Kavimandan NJ,. Confocal microscopic analysis of transport mechanisms of insulin across the cell monolayer. Int J Pharm 2008; 354: 143-148.
25. Gabizon AA, Catane R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-992.
26. Torres-Lugo M, Garcia M, Record R, Peppas NA,. pH-Sensitive hydrogels as gastrointestinal tract absorption enhancers: Transport mechanisms of salmon calcitonin and other model molecules using the Caco-2 model. Biotech Prog 2002; 18: 612-616.
27. Benival DM, Devarajan PV,. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm 2012; 423: 554-561.
28. Ke W, Zhao Y, Huang R, Jiang C, Pei Y,. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci 2007; 97: 2208-2216.
29. Yousefpour P, Atyabi F, Vasheghani-farahani E, Movahedi AM, Dinarvand R,. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anit-Her2 trastuzumab. Int J Nanomed 2011; 6: 1977-1990.
30. Bosio VE, Machain V, et al. Binding and encapsulation of doxorubicin on smart pectin hydrogels for oral delivery. Appl Biochem Biotechnol 2012; 167: 1365-1376.
31. Wang WC, Uen YH, et al. Protective effect of guggulsterone against cardiomyocyte injury induced by doxorubicin in vitro. BMC Complem AlterMed 2012; 12: 138.
32. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE,. Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haemat 2005; 131: 561-578.
33. Viswanatha SH, Wangikar U, Koti BCAHT, Ronad PM, Manjula DV,. Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats. Ind J Pharm 2011; 43: 507-511.
34. Asensio-Lopez MC, Lax A, Pascual-Figal DA, Valdes M, Sanchez-Mas J,. Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system. Free Radic Biol Med 2011; 51: 1861-1871.
35. Lowman AM, Morishita M, Kajita M, Nagai T, Peppas NA,. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci 1999; 88: 933-937.
36. Nakamura K, Murray RJ, Joseph JI, Peppas NA, Morishita M, Lowman AM,. Oral insulin delivery using P(MAA-g-EG) hydrogels: Effects of network morphology on insulin delivery characteristics. J Control Release 2004; 95: 589-599.
37. Kavimandan NJ, Losi E, Peppas NA,. Novel delivery system based on complexation hydrogels as delivery vehicles for insulin-transferrin conjugates. Biomaterials. 2006; 27: 3846-3854.
38. Carr DA, Gomez-Burgaz M, Boudes MC, Peppas NA,. Complexation hydrogels for the oral delivery of growth hormone and salmon calcitonin. Ind Eng Chem Res 2010; 49: 11991-11995.
39. Torres-Lugo M, Peppas NA,. Molecular design and in vitro studies of novel pH-sensitive hydrogels for the oral delivery of calcitonin. Macromolecules 1999; 32: 6646-6651.
40. Morishita M, Kamei N, Chiba H, Kavimandan NJ, Peppas NA, Takayama K,. Complexation hydrogels for intestinal delivery of interferon beta and calcitonin. J Control Release 2009; 134: 98-102.
41. Blanchette J, Park K, Peppas NA,. Use of complexation hydrogels for oral administration of chemotherapeutic agents. Trans Soc Biomater 2003; 89: 1606-1613.
42. Foss AC, Goto T, Morishita M, Peppas NA,. Development of acrylic-based copolymers for oral insulin delivery. Eur J Pharm Biopharm 2004; 57: 163-169.
43. Lopez JE, Peppas NA,. Effect of poly(ethylene glycol) molecular weight and microparticle size on oral insuline delivery from P(MAA-g-EG) microparticles. Drug Dev Ind Pharm 2004; 30: 497-504.
44. Peppas NA, Keys KB, Torres-Lugo M, Lowman AM,. Poly(ethylene glycol)-containing hydrogels in drug delivery. J Control Release 1999; 62: 81-87.
45. Owens III DE, Jian Y, Fang JE, Slaughter BV, Chen YH, Peppas NA,. Thermally-responsive swelling properties of polyacrylamide/poly(acrylic acid) interpenetrating polymer network nanoparticles. Macromolecules 2007; 40: 7306-7310.
46. Fisher OZ, Kim T, Dietz SR, Peppas NA,. Enhanced core hydrophobicity, functionalization and cell uptake of polybasic nanomatrices. Pharm Res 2009; 26: 51-60.
47. Owens III DE, Peppas NA,. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102.
48. Schoener CA, Hutson HN, Peppas NA,. pH-responsive hydrogels with dispersed hydrophobic nanoparticles for the delivery of hydrophobic therapeutic agents. Polymer Int 2012; 61: 874-879.
49. Varaprasad K, Mohan YM, et al. Hydrogel-silver nanoparticle composites: A new generation of microbials. J Appl Polym Sci 2010; 115: 1199-1207.
50. Yamagata T, Morishita M, et al. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. J Control Release 2006; 112: 343-349.
51. Blanchette J, Peppas NA,. Oral chemotherapeutic delivery: Design and cellular response. Ann Biomed Eng 2005; 33: 142-149.
52. Torres-Lugo M, García M, Record R, Peppas NA,. Physicochemical behavior and cytotoxic effects of p(methacrylic acid-g-ethylene glycol) nanospheres for oral delivery of proteins. J Control Release 2002; 80: 197-205.
53. Foss AC, Peppas NA,. Investigation of the cytotoxicity and insuline transport of acrylic-based copolymer protein delivery systems in contact with Caco-2 cultures. Eur J Pharm Biopharm 2004; 57: 447-455.
54. Foss AC, Peppas NA,. Investigation of the cytotoxicity and insulin transport of acrylic-based copolymer protein delivery systems in contact with caco-2 cultures. Eur J Pharm Biopharm 2004; 57: 447-455.
55. Sahlin JJ, Peppas NA,. Enhanced hydrogel adhesion by polymer interdiffusion: Use of linear poly(ethylene glycol) as an adhesion promoter. J Biomater Sci-Polym Ed 1997; 8: 421-436.
56. Jabbari E, Wisniewski N, Peppas NA,. Evidence of mucoadhesion by chain interpenetration at a poly(acrylic acid) mucin interface using ATR-FTIR spectroscopy. J Control Release 1993; 26: 99-108.
57. Peppas NA, Huang Y, Torres-Lugo M, Ward JH, Zhang J,. Physicochemical, foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng 2000; 2: 9-29.
58. Morishita M, Goto T, Takayama K, Peppas NA,. Oral insulin delivery systems based on complexation polymer hydrogels. J Drug Del Sci Technol 2006; 16: 19-24.
59. Morishita M, Goto T, Nakamura K, Lowman AM, Takayama K, Peppas NA,. Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats. J Control Release 2006; 110: 587-594.
60. Goto T, Morishita M, Kavimandan N, Takayama K, Peppas NA,. Gastrointestinal transit and mucoadhesive characteristics of complexation hydrogels in rats. J Pharm Sci 2006; 95: 462-469.
61. Serra L, Domenech J, Peppas NA,. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur J Pharm Biopharm 2009; 71: 519-528.
62. Carlstedt I, Sheehan JKAPC, Gallagher JT,. Mucus glycoproteins: A gel of a problem. Essays Biochem 1985; 20: 40-76. Cancer Institute